

Jan van Meerbeeck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1376145/jan-van-meerbeek-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

16,673
citations

64
h-index

124
g-index

299
ext. papers

20,183
ext. citations

5.6
avg, IF

6.18
L-index

#	Paper	IF	Citations
262	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	5
261	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.. <i>Lancet Oncology</i> , 2022 , 23, 540-552	21.7	2
260	Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?. <i>Oncotarget</i> , 2022 , 13, 800-809	3.3	
259	Lung cancer screening in Europe: where are we in 2021?. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2407-2417	4.4	8
258	Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675). <i>Journal of Thoracic Oncology</i> , 2021 , 16, 840-849	8.9	31
257	Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e42-e45	8.9	0
256	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. <i>PLoS ONE</i> , 2021 , 16, e0252646	3.7	
255	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. <i>Acta Clinica Belgica</i> , 2021 , 76, 224-231	1.8	1
254	Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by Mediating Mood. <i>Clinical Lung Cancer</i> , 2021 , 22, e146-e152	4.9	1
253	Evaluation of mediastinoscopy in mediastinal lymph node staging for non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021 , 32, 270-275	1.8	1
252	Molecular profiling in lung cancer associated with cystic airspaces. <i>Acta Clinica Belgica</i> , 2021 , 76, 158-161	1.8	2
251	The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. <i>Cancers</i> , 2021 , 13,	6.6	12
250	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021 , 153, 165-170	5.9	3
249	Recent developments in the treatment of small cell lung cancer. <i>European Respiratory Review</i> , 2021 , 30,	9.8	7
248	Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675). <i>Journal of Thoracic Oncology</i> , 2021 , 16, e63-e65	8.9	0
247	DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1461-1478	8.9	0
246	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020 , 37, 742-745	24.3	38

245	Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020 , 383, 931-943	59.2	201
244	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , 2020 , 21, 914-922	21.7	328
243	The scent of COVID-19: viral (semi-)volatiles as fast diagnostic biomarkers?. <i>Journal of Breath Research</i> , 2020 , 14, 042001	3.1	35
242	A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. <i>Frontiers in Oncology</i> , 2020 , 10, 1020	5.3	12
241	Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103037	7	19
240	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	57
239	ESR/ERS statement paper on lung cancer screening. <i>European Radiology</i> , 2020 , 30, 3277-3294	8	34
238	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 , 58, 1-24	3	16
237	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 344-359	8.9	27
236	Local treatment of stage IIIA-N2 nonsmall cell lung cancer: surgery and/or radiotherapy. <i>Current Opinion in Oncology</i> , 2020 , 32, 54-62	4.2	3
235	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , 2020 , 24, 113-124	4.5	15
234	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020 , 38, 602-604	24.3	5
233	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 771-779	35.1	34
232	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	5
231	Association between surgical volume and post-operative mortality and survival after surgical resection in lung cancer in Belgium: A population-based study. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 2443-2450	3.6	4
230	Diagnostic and clinical features of lung cancer associated with cystic airspaces. <i>Journal of Thoracic Disease</i> , 2019 , 11, 987-1004	2.6	16
229	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 790-798	2.2	44
228	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. <i>Cancers</i> , 2019 , 11,	6.6	42

227	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. <i>Translational Lung Cancer Research</i> , 2019 , 8, 280-285	4.4	27
226	Reply to K. Masuda et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2294-2295	2.2	0
225	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 569-580	35.1	82
224	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2019 , 20, 1702-1709	21.7	46
223	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019 , 15, e135-e141	1.8	6
222	The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data. <i>Chest</i> , 2019 , 155, 502-509	5.3	24
221	Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2019 , 20, e369-e375	4.9	9
220	Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data. <i>International Journal for Quality in Health Care</i> , 2018 , 30, 306-312	1.9	8
219	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 801-809	8.9	29
218	Imaging of urgencies and emergencies in the lung cancer patient. <i>Insights Into Imaging</i> , 2018 , 9, 463-476	5.6	8
217	Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study. <i>European Journal of Cancer Care</i> , 2018 , 27, e12747	2.4	10
216	Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2018 , 124, 19-22	5.9	7
215	Lung cancer staging: imagine fewer images. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	2
214	An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination. <i>Cytotherapy</i> , 2018 , 20, 1164-1181	4.8	7
213	Malignant pleural and peritoneal mesothelioma: clinical update 2018. <i>Translational Lung Cancer Research</i> , 2018 , 7, 505-506	4.4	0
212	Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology. <i>Insights Into Imaging</i> , 2018 , 9, 73-86	5.6	61
211	Extrapleural pneumonectomy: still indicated?. <i>Translational Lung Cancer Research</i> , 2018 , 7, 550-555	4.4	5
210	Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review. <i>Translational Lung Cancer Research</i> , 2018 , 7, 520-536	4.4	19

209	MA12.06 STELLAR Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S397-S398	8.9	7
208	A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). <i>Translational Lung Cancer Research</i> , 2018 , 7, 593-598	4.4	8
207	The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey. <i>Translational Lung Cancer Research</i> , 2018 , 7, 507-515	4.4	5
206	Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations. <i>Translational Lung Cancer Research</i> , 2018 , 7, 562-573	4.4	8
205	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S186	8.9	2
204	Real-life treatment practice for malignant pleural mesothelioma in Belgium. <i>Lung Cancer</i> , 2018 , 125, 258-264	5.9	8
203	A Multicenter Study to Assess Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting. <i>Cancers</i> , 2018 , 10,	6.6	14
202	Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report. <i>Journal of Clinical Pathology</i> , 2018 , 71, 754-756	3.9	2
201	Assessing the completeness and correctness of the registration of malignant mesothelioma in Belgium. <i>Lung Cancer</i> , 2018 , 122, 38-43	5.9	2
200	Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma. <i>Familial Cancer</i> , 2018 , 17, 569-576	3	1
199	Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. <i>Lung Cancer</i> , 2017 , 107, 100-107	5.9	94
198	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. <i>Onc Immunology</i> , 2017 , 6, e1261241	7.2	43
197	Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period. <i>Acta Chirurgica Belgica</i> , 2017 , 117, 157-163	0.9	2
196	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1109-1121	8.9	193
195	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017 , 18, 589-593	4.9	11
194	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , 2017 , 18, 1116-1125	21.7	253
193	Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. <i>Lung Cancer</i> , 2017 , 109, 74-77	5.9	13
192	Addressing the Palliative Setting in Advanced Lung Cancer Should Not Remain a Barrier: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2017 , 18, e283-e287	4.9	8

191	P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S844-S845	8.9	5
190	Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. <i>Lung Cancer</i> , 2017 , 113, 140-151	5.9	54
189	Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?. <i>Oncotarget</i> , 2017 , 8, 53751-53762	3.3	28
188	Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities. <i>Lung Cancer</i> , 2017 , 112, 109-117	5.9	7
187	Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1755-1765	8.9	6
186	O-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?. <i>Lung Cancer</i> , 2017 , 107, 91-99	5.9	9
185	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 194-207	8.9	132
184	Exhaled breath to screen for malignant pleural mesothelioma: a validation study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	18
183	Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study. <i>Oncotarget</i> , 2017 , 8, 91593-91602	3.3	42
182	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. <i>Oncotarget</i> , 2017 , 8, 89722-89735	3.3	30
181	Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. <i>Oncotarget</i> , 2017 , 8, 113673-113686	3.3	11
180	The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1615-26	8.9	57
179	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1433-46	8.9	127
178	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in cancer patients. <i>Annals of Oncology</i> , 2016 , 27, vi15	10.3	3
177	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1204-1223	8.9	333
176	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 300-11	8.9	218
175	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 666-680	8.9	116
174	Practical tools for implementing early palliative care in advanced lung cancer. <i>European Respiratory Journal</i> , 2016 , 47, 1010-2	13.6	7

173	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 651-665	8.9	148
172	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 639-650	8.9	122
171	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 681-692	8.9	74
170	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a RhemosensitivePrelapse: A single-arm phase II study (EORTC-08061). <i>European Journal of Cancer</i> , 2016, 54, 35-39	7.5	12
169	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 39-51	8.9	1888
168	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIETL). <i>PLoS ONE</i> , 2016, 11, e0147599	3.7	17
167	Bevacizumab in pleural mesothelioma: too few, too late?. <i>Translational Cancer Research</i> , 2016, 5, 120-123	3.3	8
166	Pleural Nodules and Mediastinal Lymphadenopathy in a Smoker: An Unusual Case Report. <i>Case Reports in Oncology</i> , 2016, 9, 488-492	1	1
165	Illness understanding in patients with advanced lung cancer: curse or blessing?. <i>Annals of Palliative Medicine</i> , 2016, 5, 135-8	1.7	1
164	193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥ prior systemic treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, S141	8.9	4
163	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , 2016, 48, 852-60	13.6	57
162	Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS). <i>Journal of Breath Research</i> , 2016, 10, 046001	3.1	12
161	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2089-2099	8.9	100
160	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2112-2119	8.9	116
159	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2100-2111	8.9	73
158	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2082-2088	8.9	45
157	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-17	7	19
156	Second line therapy in malignant pleural mesothelioma: A systematic review. <i>Lung Cancer</i> , 2015, 89, 223-34	3.9	45

155	Estimation of post-operative forced expiratory volume by functional respiratory imaging. <i>European Respiratory Journal</i> , 2015 , 45, 544-6	13.6	4
154	Mesothelioma treatment: Are we on target? A review. <i>Journal of Advanced Research</i> , 2015 , 6, 319-30	13	18
153	Implicit attitudes towards smoking predict long-term relapse in abstinent smokers. <i>Psychopharmacology</i> , 2015 , 232, 2551-61	4.7	54
152	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. <i>Cancer Treatment Reviews</i> , 2015 , 41, 914-24	14.4	33
151	Effects of Whole Body Vibration in Patients With COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 525-32	2	21
150	Small-cell lung cancer: local therapy for a systemic disease?. <i>Lancet, The</i> , 2015 , 385, 9-10	4.0	15
149	Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. <i>Cancer</i> , 2015 , 121, 4300-23	6.4	33
148	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 22666-79	3.3	54
147	Rehabilitation in patients with radically treated respiratory cancer: A randomised controlled trial comparing two training modalities. <i>Lung Cancer</i> , 2015 , 89, 167-74	5.9	28
146	Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. <i>The Cochrane Library</i> , 2015 , CD011430	5.2	90
145	Rebuttal from Dr van Meerbeeck. <i>Translational Lung Cancer Research</i> , 2015 , 4, 485-6	4.4	
144	Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015 , 4, 479-83	4.4	1
143	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 300-13	7	56
142	Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 898-908	4	13
141	Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study). <i>European Journal of Cancer Care</i> , 2014 , 23, 370-9	2.4	6
140	Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, e78-89	21.7	34
139	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 990-1004	14.4	60
138	A rare cause of haemoptysis. <i>Acta Clinica Belgica</i> , 2014 , 69, 69-73	1.8	

137	Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. <i>European Journal of Cancer</i> , 2014 , 50, 2771-82	7.5	7
136	Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 856-64	8.9	53
135	Routine implementation of EGFR mutation testing in clinical practice in Flanders: HERMESproject. <i>Acta Clinica Belgica</i> , 2014 , 69, 92-7	1.8	12
134	Novel treatment options in stage I non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1007-20	3.5	2
133	Radiotherapy for single station N2 NSCLC. <i>Translational Lung Cancer Research</i> , 2014 , 3, 234-7	4.4	
132	Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 475-85	2.6	47
131	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. <i>Translational Lung Cancer Research</i> , 2014 , 3, 250-61	4.4	37
130	Surgery or radiotherapy for early-stage lung cancer--a potential comparison bias. <i>Lancet Oncology</i> , 2013 , 14, e390	21.7	9
129	Novel treatment options in early-stage non-small-cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 264-5	1.6	
128	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013 , 49, 2815-22	7.5	38
127	The seventh tumour-node-metastasis staging system for lung cancer: Sequel or prequel?. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 150-8	1.6	6
126	Spirometric reference values for an East-African population. <i>Respiration</i> , 2013 , 85, 297-304	3.7	17
125	BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1081-8	5.9	23
124	Surgery in mesothelioma--where do we go after MARS?. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 525-9	8.9	26
123	A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 329-37	8.9	56
122	End of life care in lung cancer patients: not at life's end?. <i>Annals of Palliative Medicine</i> , 2013 , 2, 167-9	1.7	2
121	Initial analysis of the international association for the study of lung cancer mesothelioma database. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1631-9	8.9	255
120	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012 , 48, 2983-92	7.5	25

119	Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 99-104	1.6	
118	Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. <i>Clinical Lung Cancer</i> , 2012 , 13, 470-4	4.9	2
117	Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?. <i>Strahlentherapie Und Onkologie</i> , 2012 , 188, 564-7	4.3	27
116	Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1541-9	2.2	152
115	The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. <i>Chest</i> , 2012 , 141, 477-484	5.3	37
114	Quantitative Perfusion Scintigraphy or Anatomic Segment Method in lung cancer resection. <i>Lung Cancer</i> , 2011 , 74, 212-8	5.9	9
113	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. <i>European Journal of Cancer</i> , 2011 , 47, 2322-30	7.5	27
112	A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). <i>European Journal of Cancer</i> , 2011 , 47, 2331-40	7.5	93
111	Raltitrexed in mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1481-90	3.5	15
110	Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. <i>Respiratory Medicine</i> , 2011 , 105, 1596-605	4.6	48
109	Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 537-44	4.4	21
108	Small-cell lung cancer. <i>Lancet, The</i> , 2011 , 378, 1741-55	4.0	646
107	Investigational approaches for mesothelioma. <i>Frontiers in Oncology</i> , 2011 , 1, 22	5.3	5
106	Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 889-95	8.9	30
105	Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1930-7	8.9	66
104	European guidelines for the management of malignant pleural mesothelioma. <i>Journal of Advanced Research</i> , 2011 , 2, 281-288	13	2
103	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , 2011 , 19, 1753-60	3.9	99
102	Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2104-20	2.2	79

101	Malignant pleural mesothelioma: the standard of care and challenges for future management. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 78, 92-111	7	97
100	Malignant pleural mesothelioma: when is radiation therapy indicated?. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 551-60	3.5	6
99	A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011 , 22, 553-558	10.3	29
98	Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. <i>European Respiratory Journal</i> , 2010 , 35, 202-15	13.6	120
97	Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. <i>European Respiratory Journal</i> , 2010 , 36, 1362-9	13.6	193
96	Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v103-15	10.3	369
95	Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010 , 25, 149-54	3.9	9
94	Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2010 , 35, 479-95	13.6	444
93	Endobronchial metallic clips to guide high-dose external-beam radiotherapy in radio-occult lung cancer. <i>European Respiratory Journal</i> , 2010 , 36, 965-7	13.6	4
92	The emerging role for combined endosonography with fine needle aspiration in lung cancer staging: is the scope the right one?. <i>European Journal of Cardio-thoracic Surgery</i> , 2010 , 38, 647	3	
91	EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. <i>Annals of Oncology</i> , 2010 , 21, 692-706	10.3	109
90	Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 620-5	10.2	80
89	Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. <i>Pharmacogenomics</i> , 2010 , 11, 1053-63	2.6	43
88	Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2245-52	27.4	403
87	Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2010 , 97, 455-61	5.3	62
86	Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. <i>Lancet, The</i> , 2010 , 375, 1267-77	40	418
85	Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from the MRC LU22 multicentre randomised trial. <i>Thorax</i> , 2010 , 65, 463	7.3	6
84	Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2010 , 22, 102-11	4.2	4

83	The role of EBUS-TBNA for the assessment of Hilar lymph nodes. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 410	8.9	1
82	European guidelines for the management of malignant pleural mesothelioma 2010 , 120, 503-10		2
81	Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. <i>Clinical Chemistry</i> , 2009 , 55, 1431-3	5.5	31
80	Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 355-62	4	70
79	Palliative chemotherapy: do we need yet another end-point?. <i>European Journal of Cancer</i> , 2009 , 45, 2234-5	7.5	2
78	EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. <i>Lung Cancer</i> , 2009 , 63, 45-9	5.9	120
77	Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. <i>Lung Cancer</i> , 2009 , 65, 257-67	5.9	27
76	What is the role for surgery in patients with stage III non-small cell lung cancer?. <i>Current Opinion in Pulmonary Medicine</i> , 2009 , 15, 295-302	3	8
75	Endoscopic and endobronchial ultrasonography according to the proposed lymph node map definition in the seventh edition of the tumor, node, metastasis classification for lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1576-84	8.9	59
74	The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 792-801	8.9	329
73	EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 44-8	8.9	85
72	Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2009 , 27, e19048-e19048	2.2	15
71	The controversial role of surgery in stage III NSCLC. <i>Lancet Oncology, The</i> , 2008 , 9, 607-8	21.7	7
70	Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 531-5	10.2	89
69	Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma. <i>Clinical Cancer Research</i> , 2008 , 14, 6259-63	12.9	23
68	The sound of the parasite. Diagnosing mediastinal cysts with endoscopic ultrasound techniques. <i>Respiration</i> , 2008 , 75, 98-9	3.7	1
67	What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 199-206	3.5	4
66	Advances in the systemic therapy of malignant pleural mesothelioma. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 136-47		120

65	Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. <i>Oncologist</i> , 2008 , 13, 700-8	5.7	14
64	Screening for mesothelioma: more harm than good?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 781-2	10.2	17
63	The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 457-66	8.9	258
62	Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 764-71	8.9	41
61	The yield of endoscopic ultrasound in lung cancer staging: does lymph node size matter?. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 245-9	8.9	25
60	A guide to staging in lung cancer, but potentially misleading without attention to the details. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 209; author reply 209-10	10.2	1
59	FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 519-22	8.8	22
58	B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S349-S350	8.9	3
57	Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 442-50	9.7	512
56	Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5770-6	2.2	65
55	Response: Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1210-1211	9.7	2
54	C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S372-S373	8.9	5
53	Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1138-9	8.9	6
52	Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2007 , 19, 92-7	4.2	4
51	Short Report from the European Society of Medical Oncology: Oral Abstracts on Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 101	8.9	55
50	Predicting risk of radiation-induced lung injury. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 864-74	8.9	98
49	Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. <i>Lancet, The</i> , 2007 , 369, 1929-37	4.0	231
48	Neoadjuvant chemotherapy in early stage non-small cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 377-379	1.6	

47	Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3007-12	2.2	33
46	Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4187-93	2.2	60
45	Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. <i>Annals of Oncology</i> , 2006 , 17, 1698-704	10.3	132
44	Pemetrexed in thoracic cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 917-28	4	1
43	Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. <i>European Journal of Cancer</i> , 2006 , 42, 1391-8	7.5	10
42	Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S32-6	8.9	6
41	P-410 Prognostic factor analysis of EORTC 08983: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2005 , 49, S223	5.9	2
40	Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. <i>Lung Cancer</i> , 2005 , 49 Suppl 1, S123-7	5.9	18
39	Esophageal endoscopic ultrasound with fine-needle aspiration with an on-site cytopathologist: high accuracy for the diagnosis of mediastinal lymphadenopathy. <i>Chest</i> , 2005 , 128, 3004-9	5.3	73
38	Willingness of pulmonologists to guide COPD patients in smoking cessation. <i>Patient Education and Counseling</i> , 2005 , 57, 126-33	3.1	8
37	Morbidity and mortality in the surgery arm of EORTC 08941 trial. <i>European Respiratory Journal</i> , 2005 , 26, 192-7	13.6	74
36	Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4081-9	2.2	527
35	Raman microspectroscopic mapping studies of human bronchial tissue. <i>Journal of Biomedical Optics</i> , 2004 , 9, 1187-97	3.5	89
34	Proteomic analysis of exosomes isolated from human malignant pleural effusions. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004 , 31, 114-21	5.7	314
33	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2004 , 43, 63-9	5.9	107
32	O-273 Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): An analysis of different regimens used in EORTC 08941. <i>Lung Cancer</i> , 2003 , 41, S79-S80	5.9	5
31	Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3947-55	2.2	94
30	Curative radiotherapy for a second primary lung cancer arising after pneumonectomy -- techniques and results. <i>Radiotherapy and Oncology</i> , 2002 , 62, 21-5	5.3	14

29	Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. <i>Radiotherapy and Oncology</i> , 2002 , 63, 151-7	5.3	76
28	Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. <i>Annals of Oncology</i> , 2001 , 12, 1359-68	10.3	82
27	Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3400-8	2.2	184
26	Caelyx in malignant mesothelioma: a phase II EORTC study. <i>Annals of Oncology</i> , 2000 , 11, 697-700	10.3	49
25	Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non small-cell lung cancer after a response to induction chemotherapy. EORTC 08941. <i>Clinical Lung Cancer</i> , 2000 , 2, 69-72; discussion 73	4.9	27
24	A phase II study of gemcitabine in patients with malignant pleural mesothelioma. <i>Cancer</i> , 1999 , 85, 2577-82	6.582	113
23	Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. <i>Journal of Clinical Oncology</i> , 1998 , 16, 145-52	2.2	423
22	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2133-41	2.2	237
21	Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 1997 , 12, 224-7	3	79
20	Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. <i>European Respiratory Journal</i> , 1997 , 10, 1547-51	13.6	125
19	Surgical treatment of iatrogenic tracheal lacerations. <i>Acta Chirurgica Belgica</i> , 1997 , 97, 308-10	0.9	11
18	Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996 , 122, 619-24	4.9	16
17	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. <i>British Journal of Cancer</i> , 1996 , 74, 961-3	8.7	75
16	Role of thoracoscopy (VATS) in pleural and pulmonary pathology. <i>Acta Chirurgica Belgica</i> , 1996 , 96, 23-7	0.9	8
15	Short-term survival after major pulmonary resections for bronchogenic carcinoma. <i>Acta Chirurgica Belgica</i> , 1996 , 96, 273-9	0.9	10
14	Salmonella typhimurium empyema in an AIDS patient. <i>International Journal of STD and AIDS</i> , 1995 , 6, 287-8	1.4	2
13	Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992-1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. <i>Acta Clinica Belgica</i> , 1995 , 50, 260-8	1.8	32
12	Intrapulmonary lymph nodes in the differential diagnosis of solitary pulmonary nodules: case report and review of the literature. <i>Acta Chirurgica Belgica</i> , 1995 , 95, 130-2	0.9	3

11	Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1994 , 424, 631-4	5.1	39
10	Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). <i>Journal of Pathology</i> , 1994 , 172, 247-53	9.4	21
9	A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. <i>Annals of Oncology</i> , 1994 , 5, 653-5	10.3	35
8	A rare case of inflammatory pseudotumour of the bronchus, occurring in an achondroplastic woman. <i>European Respiratory Journal</i> , 1994 , 7, 826-8	13.6	4
7	Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium 1994 , 424, 631		17
6	Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. <i>Journal of Pathology</i> , 1992 , 167, 5-8	9.4	27
5	Massive intestinal haemorrhage due to a solitary jejunal metastasis of a primary bronchogenic tumour. <i>Acta Chirurgica Belgica</i> , 1992 , 92, 187-90	0.9	6
4	Calculation of half-life of carcinoembryonic antigen after lung tumour resection: a case report. <i>European Respiratory Journal</i> , 1991 , 4, 374-6	13.6	10
3	Disseminated lung cancer or extragonadal germ cell tumour?. <i>European Respiratory Journal</i> , 1991 , 4, 84-7	13.6	1
2	Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?. <i>European Respiratory Journal</i> , 1991 , 4, 629-31	13.6	32
1	Malignant fibrous histiocytoma of the pulmonary artery. <i>European Journal of Respiratory Diseases</i> , 1987 , 71, 321-3		